title: Management of inflammatory bowel disease in France: a nationwide survey among private gastroenterologists.
abstract: BACKGROUND
  Data on the current management of inflammatory bowel disease are scarce.
  
  
  METHODS
  This was a nationwide survey among 65 private gastroenterologists treating patients with inflammatory bowel disease in France in 2012.
  
  
  RESULTS
  A total of 375 inflammatory bowel disease patients were analysed: 48% had ulcerative colitis. One third of inflammatory bowel disease patients had a history of hospitalisation, and 40% of Crohn's disease patients had prior surgery. Two thirds of inflammatory bowel disease patients had active disease. Significantly fewer ulcerative colitis patients were treated with anti-tumour necrosis factor therapy than Crohn's disease patients (18.9% vs. 38.9%; p<0.0001). Among patients treated with anti-tumour necrosis factor, only 4.5% were receiving concomitant immunomodulators. Half of inflammatory bowel disease patients had undergone a colonoscopy within the past year. For colorectal cancer screening, random biopsies and chromoendoscopy were performed in 75% and 40% of cases, respectively. An endoscopic score was used for only 10% of inflammatory bowel disease patients. About one third of inflammatory bowel disease patients had imaging studies within the past year (magnetic resonance enterography in 65%). An abdominal computed tomography scan was prescribed for 12% of inflammatory bowel disease patients.
  
  
  CONCLUSIONS
  Many patients still have active disease in the biologics era, and the number of patients receiving combination therapy is low in private practice. Chromoendoscopy and endoscopy scores are not often used.
authors.affiliation: INSERM U954 and Department of Hepato-Gastroenterology, Université de Lorraine, France.
authors.forename: Charlène
authors.initials: C
authors.lastname: Duchesne
authors.affiliation: Department of Hepato-Gastroenterology, Clinic St Jean Languedoc, Toulouse, France.
authors.forename: Patrick
authors.initials: P
authors.lastname: Faure
authors.affiliation: SPI-EAO Laboratory, Faculty of Medicine, Nancy, France.
authors.forename: François
authors.initials: F
authors.lastname: Kohler
authors.affiliation: 23 Cours Gouffé, Marseille, France.
authors.forename: Marie-Pierre
authors.initials: MP
authors.lastname: Pingannaud
authors.affiliation: Department of Hepato-Gastroenterology, Clinic des Cèdres, Cornebarrieu, France.
authors.forename: Guillaume
authors.initials: G
authors.lastname: Bonnaud
authors.affiliation: Department of Hepato-Gastroenterology, Clinic de Courlancy, Reims, France.
authors.forename: Franck
authors.initials: F
authors.lastname: Devulder
authors.affiliation: Proctological Unit, Gastroenterological Service of CHU Bichat, APHP, Paris and Blomet Clinic, Paris, France.
authors.forename: Laurent
authors.initials: L
authors.lastname: Abramowitz
authors.affiliation: 2 Allée Robert Govi, Aubagne, France.
authors.forename: Christian
authors.initials: C
authors.lastname: Boustière
authors.affiliation: INSERM U954 and Department of Hepato-Gastroenterology, Université de Lorraine, France. Electronic address: peyrinbiroulet@gmail.com.
authors.forename: Laurent
authors.initials: L
authors.lastname: Peyrin-Biroulet
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D001706:Biopsy; D003093:Colitis, Ulcerative / Q000175:diagnosis* / Q000628:therapy*; D003113:Colonoscopy; D003424:Crohn Disease / Q000175:diagnosis* / Q000628:therapy*; D005260:Female; D005602:France; D005762:Gastroenterology; D019538:Health Care Surveys; D006760:Hospitalization; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D000069285:Infliximab; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D010818:Practice Patterns, Physicians'; D012720:Severity of Illness Index; D014057:Tomography, X-Ray Computed; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab
keywords: Inflammatory bowel disease; Management; Private practice